

A 2
A 6
B 4

4. A method for screening compounds useful for the treatment of proliferative and differentiative disorders comprising adding a compound in a purified system containing Cks1 and Skp2 or Cks1, p27 and Skp2, and detecting a change in the activity of Skp2.

A 3
A 6
B 4

7. A method for screening compounds useful for the treatment of proliferative and differentiative disorders comprising adding a compound in a purified system containing Cks1 and Skp2 or Cks1, Skp2 and a polypeptide corresponding to the carboxy terminus of the human p27 chain having the sequence NAGSVEWTPKKPGLRRRQT with or without a phosphothreonine at position 187, and detecting a change in the activity of Skp2.

REMARKS

Claims 1-9 have been examined for restriction purposes. Claims 1, 4, and 7 have been amended to more precisely define the method of screening compounds useful for the treatment of proliferative and differentiative disorders. Support for the amendments may be found at, but not limited to, page 5, lines 19-22 and page 50, line 32 through page 51, line 11.

Species Election

The Examiner has required Applicant makes a species election between the proteins p27 and Cks1 and include a listing of all claims readable thereon. In view of the submitted amendments, Applicant elects the protein Cks1 and state claims 1-9 read upon the election. This election is made without prejudice to the subject matter of any non-elected species.

Conclusion

Applicant submits and request entry of this preliminary amendment. Applicant has also responded to the Examiner's restriction requirement.

Respectfully submitted,



Leon F. Hebert

46,764
(Reg No.)

Date: November 20, 2002

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036
Tel. No. (212) 790-9090

Enclosures

**APPENDIX A: MARKED-UP CLAIMS
AS OF NOVEMBER 20, 2002**

(U.S. APPLICATION NO. 10/042,417; ATTORNEY DOCKET NO. 5914-090)

1. A method for screening compounds useful for the treatment of proliferative and differentiative disorders comprising contacting a compound with a cell or a cell extract expressing Cks1 and Skp2 [and one] or [both of p27 and] Cks1, p27 and Skp2, and detecting a change in the activity of Skp2.
4. A method for screening compounds useful for the treatment of proliferative and differentiative disorders comprising adding a compound in a purified system containing Cks1 and Skp2 [and one] or [both of p27 and] Cks1, p27 and Skp2, and detecting a change in the activity of Skp2.
7. A method for screening compounds useful for the treatment of proliferative and differentiative disorders comprising adding a compound in a purified system containing Cks1 and Skp2 [and one] or [both of] Cks1, Skp2 and a polypeptide corresponding to the carboxy terminus of the human p27 chain having the sequence NAGSVEWTPKKPGLRRRQT with or without a phosphothreonine at position 187[and Cks1], and detecting a change in the activity of Skp2.